Provention Bio Inc. Common Stock (NASDAQ:PRVB)

Real-time price: | Most recent change:0.00%

Provention Bio, Inc. is a biopharmaceutical company. It focuses on development of novel therapeutics and solutions to intercept and prevent immune-mediated disease. The company's product pipeline consists of PRV-031, PRV-6527, PRV-300, PRV-3279 and PRV-101 which are in clinical stage. Provention Bio, Inc. is based in NJ, United States....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 25 April 2026

Blog+More

The lean CEO encourages iterative continuous improvements and collaborative teams to innovate around core value streams.

Monica McNeil

2020-07-12 08:30:00 Sunday ET

The lean CEO encourages iterative continuous improvements and collaborative teams to innovate around core value streams.

The lean CEO encourages iterative continuous improvements and collaborative teams to innovate around core value streams. Jacob Stoller (2015)  

+See More

House Judiciary Committee summons senior executive reps of the tech titans to assess online platforms and their market power.

Peter Prince

2019-08-18 11:33:00 Sunday ET

House Judiciary Committee summons senior executive reps of the tech titans to assess online platforms and their market power.

House Judiciary Committee summons senior executive reps of the tech titans to assess online platforms and their market power. These companies are Facebook,

+See More

European Commission President Ursula von der Leyen now protects the European circular economy and green growth from 2020 to 2050.

Dan Rochefort

2019-12-22 08:30:00 Sunday ET

European Commission President Ursula von der Leyen now protects the European circular economy and green growth from 2020 to 2050.

European Commission President Ursula von der Leyen now protects the European circular economy and green growth from 2020 to 2050. The new circular economy r

+See More

What are the top global risks in trade, finance, and technology as of mid-2023?

Andy Yeh Alpha

2023-05-31 11:27:00 Wednesday ET

What are the top global risks in trade, finance, and technology as of mid-2023?

What are the top global risks in trade, finance, and technology? In this macro report, we focus on the current global risks from inflation and growth con

+See More

President Trump tweets that he asks the SEC to assess the practical implications of switching to a 6-month corporate disclosure cycle.

John Fourier

2018-08-17 11:45:00 Friday ET

President Trump tweets that he asks the SEC to assess the practical implications of switching to a 6-month corporate disclosure cycle.

In accordance with the extant corporate disclosure rules and requirements, all U.S. public corporations have to report their balance sheets, income statemen

+See More

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Rose Prince

2018-10-15 09:33:00 Monday ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications an

+See More